New combo therapy hopes to tackle tough bile duct cancer

NCT ID NCT06230471

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy or the targeted drug lenvatinib can help people with advanced biliary tract cancer live longer and control their tumors better. The study will enroll 60 adults whose cancer has spread and cannot be removed by surgery. Participants will receive one of several treatment combinations, and researchers will monitor how well the tumors respond and how safe the treatments are.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (immunotherapy) combined with lenvatinib or chemotherapy (gemcitabine and oxaliplatin)
What this could lead to: If successful, this could point toward a more effective first-line treatment for advanced biliary tract cancer, potentially improving survival and tumor control.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The combination therapies may cause significant side effects, and there is no guarantee they will work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma of gallbladder and extrahepatic biliary tract biliary tract cancer biliary tract neoplasm extrahepatic bile duct carcinoma gallbladder cancer intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT NEOPLASMS IMMUNOTHERAPY

Contacts and locations

Locations

Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH)
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.